JP Morgan Chase
GPCR icon

JP Morgan Chase’s Structure Therapeutics GPCR Stock Holding History

JP Morgan Chase’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$17.9M Buy
546,189
+542,205
+13,610% +$25.4M ﹤0.01% 2320
2026
Q2 		$206K Sell
3,984
-208,819
-98% -$9.24M ﹤0.01% 5600
2026
Q1 		$9.35M Buy
212,803
+199,847
+1,543% +$13.7M ﹤0.01% 2749
2025
Q4 		$901K Sell
12,956
-45,192
-78% -$1.85M ﹤0.01% 4677
2025
Q3 		$1.63M Buy
58,148
+15,706
+37% +$313K ﹤0.01% 4234
2025
Q2 		$880K Sell
42,442
-91,797
-68% -$2.02M ﹤0.01% 4457
2025
Q1 		$2.32M Buy
134,239
+101,924
+315% +$2.5M ﹤0.01% 3766
2024
Q4 		$876K Sell
32,315
-1,621
-5% -$57.5K ﹤0.01% 4721
2024
Q3 		$1.49M Buy
33,936
+25,500
+302% +$986K ﹤0.01% 4228
2024
Q2 		$331K Sell
8,436
-15,995
-65% -$657K ﹤0.01% 4901
2024
Q1 		$1.05M Buy
24,431
+16,585
+211% +$699K ﹤0.01% 4320
2023
Q4 		$320K Sell
7,846
-31,713
-80% -$1.82M ﹤0.01% 5064
2023
Q3 		$1.99M Buy
+39,559
New +$1.27M ﹤0.01% 3540

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Capitolis Liquid Global Markets
Capitolis Liquid Global Markets New York $22.4B AUM 40.52% 1-Year Est. Return
Pacific Heights Asset Management
Pacific Heights Asset Management San Francisco, California $3.1B AUM 37.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

JP Morgan Chase's GPCR Position: Q3 2026 in Review

JP Morgan Chase increased its Structure Therapeutics (GPCR) stake by 13,610% in Q3 2026, buying an estimated $25.4M and bringing the position to 546,189 shares worth $17.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2320.

JP Morgan Chase first reported a position in GPCR in Q3 2023 and has held it in 13 quarters since. 88 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

  • JP Morgan Chase held 546,189 shares of Structure Therapeutics worth $17.9M as of Q3 2026.
  • JP Morgan Chase bought 542,205 Structure Therapeutics shares in Q3 2026, an estimated $25.4M.
  • Structure Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #2320 holding.
  • JP Morgan Chase first reported a position in Structure Therapeutics in Q3 2023 and has held it in 13 quarters since.
  • 88 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.